@article{6c6b7dbbfc5e43fabb0a457b03309736,
title = "T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy",
abstract = "T cells are integral components of the adaptive immune system, and their responses are mediated by unique T-cell receptors (TCR) that recognize specific antigens from a variety of biological contexts. As a result, analyzing the T-cell repertoire offers a better understanding of immune responses and of diseases like cancer. Next-generation sequencing technologies have greatly enabled the high-throughput analysis of the TCR repertoire. On the basis of our extensive experience in the field from the past decade, we provide an overview of TCR sequencing, from the initial library preparation steps to sequencing and analysis methods and finally to functional validation techniques. With regards to data analysis, we detail important TCR repertoire metrics and present several computational tools for predicting antigen specificity. Finally, we highlight important applications of TCR sequencing and repertoire analysis to understanding tumor biology and developing cancer immunotherapies.",
author = "Frank, {Meredith L.} and Kaylene Lu and Can Erdogan and Yi Han and Jian Hu and Tao Wang and Heymach, {John V.} and Jianjun Zhang and Alexandre Reuben",
note = "Funding Information: A. Reuben was supported by the Exon 20 Group, Rexanna{\textquoteright}s Foundation for Fighting Lung Cancer, the Waun Ki Hong Lung Cancer Research Fund, MD Anderson{\textquoteright}s Lung Cancer Moon Shot, the Petrin Fund, the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center, the Happy Lungs Project, RETpositive/LUNGevity (FP00015320), and the Cancer Prevention & Research Institute of Texas (RP210137). Funding Information: J.V. Heymach reports other support from AstraZeneca, EMD Serono, Boehringer-Ingelheim, Catalyst, Genetech, GlaxoSmithKline, Hengrui Therapeutics, Eli Lilly, Spectrum, Sanofi, Takeda, Mirati Therapeutics, Bristol Myers Squibb, BrightPath Biotherapeutics, Janssen Global Services, Pneuma Respiratory, RefleXion, and Chugai Pharmaceuticals outside the submitted work. J. Zhang reports personal fees from AstraZeneca, Geneplus, Hengrui, Innovent, Merck, and Roche; grants and personal fees from Johnson and Johnson and Novartis; and grants from OrigMed outside the submitted work. A. Reuben reports personal fees from Adaptive Biotechnologies outside the submitted work. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright} 2022 The Authors.",
year = "2023",
month = mar,
day = "15",
doi = "10.1158/1078-0432.CCR-22-2469",
language = "English (US)",
volume = "29",
pages = "994--1008",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",
}